Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Waleed Hassanein: Thank you so much, Hannah. As always, joining me today is Gerardo Hernandez, our Chief Financial Officer. Since inception, TransMedics has been relentless in our pursuit to transform organ transplant therapy by increasing utilization of donor organs and improving the clinical outcomes of transplant patients throughout -- through technology and service innovation and by disrupting the status quo.
Moby summary of TransMedics Group, Inc.'s Q1 2026 earnings call
TransMedics Group (NASDAQ:TMDX) reported first-quarter 2026 revenue of $174 million, up about 21% year over year and 8% sequentially, as the company continued to expand adoption of its Organ Care System (OCS) platform and its National OCS Program (NOP) logistics model while increasing investment in
While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
TransMedics (TMDX) delivered earnings and revenue surprises of -51.46% and -0.99%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
TransMedics Group unveiled its Controlled Hypothermic Organ Preservation System, or CHOPS, a new active cooling device for donor organ storage. The company outlined plans for CHOPS to serve as the control arm in the ENHANCE Heart Part B and DENOVO Lung clinical trials. These updates add a new organ preservation platform alongside TransMedics Group's existing transplant technology programs. TransMedics Group (NasdaqGM:TMDX) is drawing attention with CHOPS at a time when its share price...
Is TMDX a good stock to buy? We came across a bullish thesis on TransMedics Group, Inc. on Grillo Insights’s Substack by Eric García. In this article, we will summarize the bulls’ thesis on TMDX. TransMedics Group, Inc.’s share was trading at $116.11 as of April 15th. TMDX’s trailing and forward P/E were 23.84 and 46.51 respectively according to Yahoo Finance. […]
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
